Sex-stratified genomic structural equation models of posttraumatic stress inform PTSD etiology

Ashley Moo-Choy¹, Murray B Stein²⁻⁴, Joel Gelernter⁵⁻⁸, Frank R Wendt^{1,9,10,*}

¹ Department of Anthropology, University of Toronto, Mississauga, ON, Canada

² VA San Diego Healthcare System, Psychiatry Service, San Diego, CA, USA

³ Department of Psychiatry, University of California San Diego, La Jolla, CA, USA

⁴ Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA

⁵ Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA

⁶VA CT Healthcare System, West Haven, CT, USA

⁷ Department of Genetics, Yale School of Medicine, New Haven, CT, USA

⁸ Department of Neuroscience, Yale School of Medicine, New Haven, CT, USA

⁹ Biostatistics Division, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

¹⁰ Forensic Science Program, University of Toronto, Mississauga, ON, Canada

*Correspondence: Frank R Wendt (<u>frank.wendt@utoronto.ca</u>; ORCID: <u>https://orcid.org/0000-0002-2108-</u> 6822)

Short title: genomic models of PTSD symptoms by sex

Keywords: PTSD, posttraumatic stress, genomic structural equation models, sex-differences

ABSTRACT

Posttraumatic stress disorder (PTSD) affects 3.9%-5.6% of the worldwide population, with welldocumented sex-related differences. While psychosocial and hormonal factors affecting sex differences in PTSD and posttraumatic stress (PTS) symptom etiology have been explored, there has been limited focus on genetic bases of these differences. Many symptom combinations may confer a PTSD diagnosis. We hypothesized that these symptom combinations have sex-specific patterns, the examination of which could inform etiological differences in PTSD genetics between males and females. To investigate this, we performed a sex-stratified multivariate genome-wide association study (GWAS) in unrelated UK Biobank (UKB) individuals of European ancestry. Using GWAS summary association data, genomic structural equation modeling was performed to generate sex-specific factor models using six indicator variables: trouble concentrating, feeling distant from others, irritability, disturbing thoughts, upset feelings, and avoidance of places/activities which remind the individual of a traumatic event. Models of male and female PTSD symptoms differed substantially (local standardized root mean square difference=3.12) and significantly ($\chi^2(5)=28.03$, p=3.6x10⁻⁵). Independent two-factor models best fit the data in both males and females; these factors were subjected to GWAS in each sex, revealing three genome-wide significant loci in females, mapping to SCAND3, WDPCP, and FAM120A. No genome-wide significant loci were identified in males. All four PTS factors (2 in males and 2 in females) were heritable (p<0.05): male PTS-f₁ h^2 -SNP=1.85%, male PTS-f₂ h²-SNP=1.47%, female PTS-f₁ h²-SNP=3.87%, female PTS-f₂ h²-SNP=3.53%. Male PTS- f_1 was enriched for medication-related putative causal relationships (3.73-fold, p=0.032) while male PTS- f_2 was enriched for body structure (2.84-fold, p=5.512x10⁻⁷) and cognitive (3.22-fold, p=0.009) putative causal relationships. In females, PTS-f₁ was enriched for metabolic putative causal relationships (28.08-fold, p=0.035). By assessing the relationship between sex and PTSD symptoms, this study informs correlative and putatively causal etiological differences between males and females which support further investigation of sex differences in PTSD genetics.

INTRODUCTION

Posttraumatic stress disorder (PTSD) affects an estimated 3.9% to 5.6% of the worldwide population (1). In individuals with severe mental illness, an estimated 30% also suffer from PTSD as a result of traumatic experiences (2). The Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) defines traumatic exposure as either experiencing, witnessing, and/or learning of a traumatic event involving friends or family, or by repetitive personal exposure, such as by first responders or police officers (3). Diagnosis of PTSD after trauma exposure requires an individual to experience intrusive (aka reexperiencing) memories of the traumatic event(s), hyperarousal, avoidance of reminders of the event(s), and negative cognitions and mood related to the trauma for a period of at least one month, resulting in significant distress and/or functional impairment.

Trauma exposure and PTSD are both heritable, meaning genetic factors explain a portion of trait variation in the population (4). Trauma exposure affects people differently based on sex, gender identity, and age of exposure (5,6). Women have at least two times higher lifetime risk of PTSD, in part due to exposure to different types of trauma than men (e.g., rape and intimate partner violence) and age at trauma exposure (e.g., childhood sexual abuse). There have been both biological (e.g. hormonal) and psychosocial hypotheses as to the cause of sex-based differences in PTSD onset, symptomatology, and treatment, but sex-based empirical biological data are lacking (4). Women are more likely to experience sexual and familial trauma at younger ages, while men are more likely to be exposed to trauma in adulthood. Conversely, some studies suggest that the increased prevalence of PTSD in women is due to the differing symptomatology of PTSD relative to men (7). For example, women report more re-experiencing symptoms than men, motivating the exploration of different etiologies and patterns of symptom clustering.

Previous genome-wide association studies (GWAS) of PTSD have appreciated these known sex differences in exposure to trauma and PTSD symptom presentation. The SNP-based heritability of PTSD in women is consistently non-zero and detectable even in early studies of PTSD with limited sample size (8,9). Conversely, studies in men required larger sample sizes to detect a significant SNP-based heritability estimate (8,9). Independent of sex and/or gender differences in PTSD presentation, PTSD genetics correlates with genetic factors influencing depression (10), anxiety (11), attention deficit hyperactivity disorder (12), schizophrenia (8), bipolar disorder (13), and other mental disorders. Prior reports postulate that various combinations of PTSD risk factors, including symptom patterns and severity, explain a large

portion of sex differences in PTSD etiology (14). As we recognize the phenotypic differences in PTSD between males and females, we investigated whether we could identify a genetic basis of these differences.

DSM-5 criteria enable over 636,000 possible diagnostic combinations of PTSD symptoms, and prior work demonstrates substantial diagnostic overlap between patients (15,16). We hypothesized that PTSD symptoms overlap in a sex-specific manner and that this pattern of overlap informs sex-specific disorder etiology. We used genomic structural equations modelling (gSEM) to model multivariate genetic architecture of PTSD symptoms separately in males and females. We report sex-specific factor structures whose genetic architecture differentially overlaps with features of the human phenome that inform differences in PTSD etiology between males and females.

METHODS

Data Description and Factor Modeling

The UK Biobank (UKB) is a population-based cohort of >500,000 participants with deep phenotyping of lifestyle factors, mental and physical health outcomes, anthropometric measurements, and other traits. This study used GWAS summary data for posttraumatic stress (PTS) phenotypes from unrelated European ancestry participants adjusted for the first 20 genetic principal components, age, and age². Sex was not included as a covariate due to the sex stratified design of this study.

gSEM models the multivariate genetic architecture of sets of traits considering their genetic covariance structure (17). Using gSEM, a multivariable GWAS was performed with six PTS traits based on their unique factor structure in males and females. The six factor indicators were questions from the UKB thoughts and feelings section of the online Mental Health Questionnaire and have been previously described by Davis et al. (Table S1) (18). Five questions asked about how often participants were bothered by: (i) *avoiding activities or situations because they remind them of stressors* ("Avoid", N=117,868, 56% female), (ii) *feeling distant or cut off from others* ("Distant"; N=52,822; 63% female), (iii) *feeling irritable or having angry outbursts* ("Irritable", N=52,816, 63% female), (iv) *repeated, disturbing memories, thoughts, or images of a stressful experience* ("Thoughts", N=117,900, 56% female), and (v) *feeling very upset when something reminded them of a stressor* ("Upset", N=117,893, 56% female). Participants responded to these questions with a rating from 0 = "not at all" to 4 = "extremely." The sixth question

asked about how bothered participants were by *trouble concentrating on things, such as reading or watching television*, over the last two weeks ("Concentrate", N=117,899, 56% female). Participants responded to this question with a rating from 1 = "not at all" to 4 = "nearly every day."

Multivariable linkage disequilibrium score regression (LDSC) was used to obtain genetic covariance and sampling matrices using a European ancestry linkage disequilibrium reference panel from the 1000 Genomes Project. Factor modeling used diagonally weighted least squares estimation and promax rotation. Exploratory factor analysis (EFA) was used to evaluate a common factor and a two-factor structure for the six traits in males and females. From EFA, confirmatory factor analysis (CFA) was performed using all indicator traits with factor loadings > 0.3. Four model fit statistics were compared to assess the suitability of a one-factor versus two-factor model: chi-squared (χ^2), comparative fit index (CFI), Akaike information criterion (AIC), and standardized root mean square residual (SRMR). The χ^2 statistic indexes whether modelled genetic covariance differs from an empirical matrix. CFI tests whether the proposed model fits better than a model that assumes all indicators are heritable but uncorrelated. AIC measures relative model fit and may be used to compare multiple models. SRMR measures approximate model fit calculated as the standardized root mean square difference between implied and observed correlations among covariance matrices. Each fit statistic has strengths and weaknesses, so we considered several features in deciding the best model. When comparing one- and two-factor models, the superior model in our study had a low AIC value, low SRMR, and high CFI.

Comparing Male and Female Factor Structures

Models of PTS in males and females were compared using local standardized root mean-square difference (localSRMD) (19). Briefly, localSRMD indexes the extent to which each parameter in the model (i.e., factor loadings) differs across groups, here defined as male and female. To compare across sex, a covariance matrix was constructed using all PTS indicators from both sexes (twelve total indicators) and subsequently used to estimate unconstrained (all indicators are estimated freely) and constrained models (the indicators we compare across models were forced to be equal). LocalSRMD values are interpretable similar to Cohen's *d*, so localSRMD >0.1 and <0.3 indicated a small difference between models, localSRMD >0.5 indicated a large difference between models. LocalSRMD < 0.1 indicated a trivial difference. A χ^2 nested model comparison

was performed to test the exact equivalence of parameters by sex. A nontrivial localSRMD and significant χ^2 (p<0.05) must both be true to render the models appreciably different across sex.

Annotating PTS Factor GWAS

GWAS for PTS factors 1 (PTS- f_1) and 2 (PTS- f_2) were annotated using Multi-marker Analysis of GenoMic Annotation (MAGMA v1.08) implemented in FUMA v1.5.3 using 2-kb positional mapping around each lead SNP. Linkage disequilibrium independent loci were defined by lead SNPs with p<5x10⁻⁸ and surrounding SNPs with r^2 >0.6 with the lead SNP. Enrichment of tissue transcriptomic profiles was tested using to GTEx v8 for investigation of 54 general tissue types and BrainSpan for investigation of developmental stage and age of brain tissues. Multiple testing correction was applied using FDR (5%) considering all tissue-types or cell-types tested in both sexes. Genome-wide significant SNPs had association $p<5x10^{-8}$ while genome-wide significant genes had association $p<2.58x10^{-6}$ based on a Bonferroni correction for the 19,365 protein-coding genes mapped by FUMA-MAGMA. Significant SNPs and genes for each PTS factor were subjected to phenome-wide association testing in the GWAS Atlas PheWAS browser. Enrichment of associated phenotypes was determined using hypergeometric tests of 4,756 traits separated into 25 trait domains: activities (N=137), aging (N=5), body structures (N=18), cardiovascular (N=162), cellular (N=1,143), cognitive (N=78), connective tissue (N=14), dermatological (N=31), ear, nose, and throat (N=6), endocrine (N=67), environmental (N=92), gastrointestinal (N=42), hematological (N=38), immunological (N=365), infection (N=3), metabolic (N=1,259), mortality (N=46), muscular (N=5), neoplasms (N=49), neurological (N=437), nutritional (N=46), ophthalmological (N=28), psychiatric (N=321), reproduction (N=76), respiratory (N=74), skeletal (N=194), and social interactions (N=20).

Linkage Disequilibrium Score Regression (LDSC)

LDSC was used to estimate the h^2 -SNP of each PTS-factor in each sex based on the 1000 Genomes Project European ancestry reference panel. The major histocompatibility complex region was excluded from these analyses due to its complex linkage disequilibrium structure. LDSC also was used to estimate cross-trait genetic correlation (r_g) with respect to 523 UKB traits with suitably powerful h^2 -SNP estimates in both males and females (h^2 -SNP Z-score>4 in both sexes). Two-sided Z-tests were used to compare r_g estimates between the two factors within each sex. Traits correlated with one factor (FDR<0.05) but not

with the other factor (P>0.05) and with a significant difference between r_g were considered "specific" to that factor.

Latent Causal Variable Modeling

The Latent Causal Variable (LCV) method was used to identify putative causal relationships between PTS-f1 and PTS-f2 and each phenotype from the UKB. Briefly, LCV distinguishes genetic correlation from causation by modeling a latent mediator with a causal effect on each trait (20). All genetic causality proportions (gcps) between two traits were estimated with the PTS factor as trait 1 and the UKB trait as trait 2. With this coding in mind, the posterior mean gcps reported here are interpreted as follows: (i) |gcp| between 0.7-1 indicates a fully causal relationship, (ii) gcp>0 indicates that PTS causes trait 2, (iii) gcp<0 indicates that PTS is caused by trait 2, and (iv) the causal effect (i.e., "increase" or "decrease" in risk) for significant gcps were deduced from the genetic correlation estimate (21,22). Multiple testing correction was performed using a false discovery rate of 5%. Assessing all traits at an LCV two-tailed p<0.05, hypergeometric testing was performed to determine enrichment of putatively causal trait domains based on six relevant assessments of the data: (i) PTS-f₁ and PTS-f₂ cause trait 2; (ii) trait 2 causes PTS- f_1 and PTS- f_2 ; (iii) all traits with significant putative causal effects with PTS- f_1 and PTS- f_2 but insignificant gcp differences measured by two-sided Z-tests, herein listed as "concordant"; (iv) traits with significant gcps relative to one PTS factor and not the other, and significant gcp differences measured by two-sided Z-tests, herein listed as "discordant"; (v) PTS-f₁ specific; (vi) PTS-f₂ specific. Two-sided Z-tests were used to compare gcp estimates between the two factors within each sex.

RESULTS

Structure of PTS factors in males and females

Using GenomicSEM, common factor and two-factor models were explored using posttraumatic stress symptoms in males and females. EFAs suggested two-factor models fit best in both males (cumulative variance explained for 1-factor model = 0.762, 2-factor model = 0.914) and females (cumulative variance explained for 1-factor model = 0.796, 2-factor model = 0.887; Table S2). Models of male and female PTS symptoms differed substantially (localSRMD = 3.12) and significantly ($\chi^2(5) = 28.03$, p = 3.6x10⁻⁵). The unstandardized loading for the *thoughts* indicator differed most between males and

females. Freeing this parameter reduced localSRMD to 2.30, which still indicated a large difference between sexes, but the difference was no longer significant by χ^2 testing ($\chi^2(4) = 9.44$, p = 0.051). With the relaxed model (i.e., freeing the *thoughts* indicator) we established partial invariance of the factors, but were underpowered to detect sex differences in loadings for specific indicators of PTS-f₁ and f₂. However, there were noteworthy qualitative patterns that differed by sex. Male PTS-f₁ largely reflected *irritability* (loading=1, se=0.417, p=0.015) and *feeling distant* (loading=0.95, se=0.233, p=0.001) while PTS-f₂ represented *upset feelings* (loading=0.938, se=0.462, p=0.042). Female PTS-f1 reflected *trouble concentrating* (loading=0.995, se=0.096, p=3.72x10⁻²⁵), *avoidance* (loading=0.957, se=0.091, p=4.17x10⁻²⁶), and *feeling distant* (loading=0.954, se=0.258, p=2.16x10⁻⁴). CFAs were constructed for all four models (Table S3) and support the separate two-factor constructions for both males and females (Figure 1, Figure S1, and Table S4). These models were used for GWAS of each factor.

Genetic architecture of male and female PTS factors

Each PTS factor from males and females had non-zero SNP-heritability estimates: male PTS-f₁ h^2 -SNP=1.85%, se=0.33, male PTS-f₂ h^2 -SNP =1.47%, se=0.32, female PTS-f₁ h^2 -SNP =3.87%, se=0.43; female PTS-f₂ h^2 -SNP =3.53%, se=0.37. There were two loci associated with female PTS-f₁: (i) rs146918648 (β =-0.072, p=6.73x10⁻⁹) positionally mapped to an intronic region of *SCAND3*, previously detected in studies of well-being, depressive symptoms, and positive affect (Tables S5 and S6) and (ii) rs72813410-C (β =-0.08, P=1.94x10⁻⁸) which positionally mapped to a intronic region of *WDPCP*, previously detected in studies of smoking initiation and age of first sexual intercourse (Tables S7 and S8). Gene-based association testing of female PTS-f₁ revealed an association with *FAM120A* (Z=4.56, P=2.52x10⁻⁶), which has been detected previously in studies of neuroticism, loneliness, and comparative body size at age 10 (Table S9). The GWAS for female PTS-f₁ was enriched for transcriptomic effects from spinal cord cervical c-1 (β =0.015, p=0.035), hippocampus (β =0.013, p=0.039), hypothalamus (β =0.013, p=0.040), and substantia nigra (β =0.013, p=0.049; Table S10), while the GWAS of female PTS-f₂ was enriched for vaginal transcriptomic effects (β =0.018, p=0.046).

There were no genome-wide significant loci associated with either male PTS factor (which showed lower heritabilities than the female factors), but the genome-wide signal of male PTS-f₂ was weakly

enriched for cerebellar (β =0.009, p=0.049), aortic (β =0.018, p=0.024), and tibial artery transcriptomic signatures (β =0.021, p=0.008; Table S10).

Genetic Correlation

After multiple testing correction (FDR<0.05), 199 of 523 traits were genetically correlated with male PTS-f₁ and PTS-f₂, respectively (Table S11). These were enriched for psychiatric traits (2.03-fold, $p=1.29x10^{-14}$; Table S12). There were 10 traits associated with male PTS-f₁ (FDR<0.05) but not associated with male PTS-f₂ (P>0.05). The strongest of these was with *number of full sisters* (UKB Field ID 1883; r_g with male PTS-f₁=0.439, p=0.003 and with male PTS-f₂=0.238, P=0.133). There were 28 traits associated with male PTS-f₂ (FDR<0.05) but not associated with male PTS-f₁ (p>0.05). These were enriched for cognitive (4.66-fold, p=4.34x10⁻⁴), musculoskeletal (2.66-fold, p=0.022), and nutritional (2.85-fold, p=0.016) trait domains. The strongest of these was with *fluid intelligence (positional arithmetic*, UKB Field ID 4968; r_g with male PTS-f₁=-0.175, p=0.160 and with male PTS-f₂=-0.477, p=0.002).

After multiple testing correction (FDR<0.05), there were 274 traits genetically correlated with female PTS-f₁ and PTS-f₂ (Table S11). These were enriched for respiratory (1.64-fold, p=9.29x10⁻¹²), gastrointestinal (1.23-fold, p=0.001), and urogenital (1.49-fold, p=0.047) trait domains (Table S12). This set of traits was also depleted for psychiatric traits (7.34-fold, p=2.31x10⁻⁷). There were 29 traits associated with female PTS-f₁ (FDR<0.05) but not associated with female PTS-f₂ (p>0.05). These traits were enriched for body structures (3.64-fold, p=9.67x10⁻⁵) – the strongest result from this trait domain was *whole body water mass* (UKB Field ID 23102; r_g with female PTS-f₁=0.128, p=5.13x10⁻⁴ and with female PTS-f₂=0.074, p=0.056). There were 18 traits associated with female PTS-f₂ (FDR<0.05) but not associated with female PTS-f₁ (FDR<0.05). These were enriched for cardiovascular traits (3.64-fold, p=0.036) and ophthalmological traits (8.50-fold, p=0.018) – the strongest genetically correlated trait from these domains was *coronary atherosclerosis* (UKB Field ID I9_CORATHER; r_g with female PTS-f₁=0.146, p=0.126 and with female PTS-f₂=0.219, P=0.023).

Putative Causal Relationships

LCV was used to determine if genetic correlations suggested a putatively causal effect mediated by a latent variable. After multiple testing correction, there were many putative causal relationships with

each PTS factor (male PTS-f₁ = 99; male PTS-f₂ = 166; female PTS-f₁ = 34; female PTS-f₂ = 80). In males and females, nearly all analysis strata were enriched for putative causal relationships with psychiatric traits (Tables S13-S15); however, male PTS-f₂-specific results were depleted for psychiatric traits (3.42-fold depletion, p=8.83x10⁻⁷). Male PTS-f₁-specific traits were enriched for traits related to medication intake (3.73-fold, p=0.032) while male PTS-f₂-specific traits were enriched for body structure (2.84-fold, p=5.51x10⁻⁷) and cognitive (3.22-fold, p=0.009) causal relationships. In females, PTS-f₁-specific traits were enriched in the metabolic domain (28.08-fold enrichment, p=0.035).

Of the medication-related traits specifically enriched in male PTS-f₁, we observed conflicting putative causal estimates with respect to omeprazole use. General omeprazole use was putatively causal for male PTS- f_1 (gcp=-0.05, p=0.005); however, omeprazole use ascertained in the context of pain relief, constipation, and/or heartburn was caused by PTS- f_1 at much larger magnitude (gcp=0.39, p=0.020). The body structure traits with putative causal effects relative to male PTS-f₂ were mainly for measures of body fat percentages (including whole body, arms, legs, and waist), as well as body mass index (BMI; gcp=0.8; p=3.41x10⁻⁸) increasing as a result of PTS-f₂. Additionally, in the cognitive domain, PTS-f₂ had causal effects with decreased performance on fluid intelligence (gcp=0.56; $p=1.53x10^{-6}$) and reaction time (gcp=0.89; p=6.24x10⁻¹⁰) tests. The most significant male PTS-f₂-specific findings indicated that PTS-f₂ causes repeated disturbing thoughts of stressful experiences (gcp=0.9; $p=6.24x10^{-10}$) and increased risk-taking behaviour (gcp=0.44; p=2.48x10⁻⁸). In females, enrichment was detected for metabolic traits in PTS- f_1 , in which the PTS-f₁-specific association was high cholesterol having a causal effect on PTS-f₁ (gcp=-0.78; $p=1.04x10^{-7}$). Female $PTS-f_2$ had many specific putative causal relations with psychiatric traits; the most significant of which were anxiety and depression-related: PTS-f₂ causing nervous feelings (gcp=-0.53; p=2.16x10⁻³²) and extended periods of unenthusiasm/disinterest (gcp=-0.95; $p=3.13x10^{-30}$) and tiredness/lethargy causing PTS- f_2 (gĉp=-0.91; p=5.09x10⁻²¹).

DISCUSSION

Through multivariate modelling of PTSD symptom GWAS and assessment of genetic correlates and putative causal phenotypes related to each symptom factor, our study identified patterns of phenotypic differences which could inform sex differences in PTSD etiology. Consistent with prior literature, female PTS factors had slightly higher SNP-based h^2 estimates than male PTS factors. Looking

at factor structure, male PTS factors were uncorrelated while females PTS factors were correlated. These findings may in part be attributed to women reporting more severe PTS symptoms relative to men. Our novel approach to compare male and female factor structures in UKB indicated that differences in factor loadings of PTSD symptoms do exist across males and females. Though model comparisons support these differences, we were underpowered to identify which factors differ (16). However, the pattern of indicators that load onto each factor show genetic differences between sexes that are reinforced among phenotype-level factor modeling. Overstreet et al. demonstrate among military veterans (92.2% male) that irritability and difficulty concentrating cluster together in a dysphoric arousal factor (16). Despite using a civilian cohort to measure PTSD symptoms, our genetic investigation supports this clustering. However, we showed using genetic data that irritability and difficulty concentrating and strongly load onto distinct factors. Below we detail findings from GWAS of each PTS factor to understand what each latent feature of PTS represents in the context of health and disease relevance.

Across all four GWAS (two each in males and females), we identified two genome-wide significant loci associated with female f₁: *SCAND3* (SCAN domain containing 3) and *WDPCP* (WD repeat containing planar cell polarity effector). SCAND3 was previously identified as potentially diagnostic for hepatocellular carcinoma, a cancer of the liver (23). As cancer may serve as an index trauma, SCAND3 may serve as an indicator of PTS severity, though this relationship requires dedicated testing (24–26). We identified *WDPCP* (rs72813410-C) as a risk decreasing variant for female PTS-f₁. This gene was previously identified as a risk-increasing genome-wide significant finding in a cross-disorder study of the impulsivity-compulsivity spectrum (comprised of Tourette Syndrome, obsessive compulsive disorder, ADHD, and autism spectrum disorder) (27). WDPCP also associated with DNA methylation in past child soldiers (28) and tinnitus prevalence (29). These findings, along with lack of enrichment for psychiatric genetic correlates and enrichment of putatively causal relationships with body structures, support the identity of female PTS-f₁ as a general factor of non-psychiatric disease/disorder risk. Despite lack of individual significant loci identified in the GWAS of female PTS-f₂, male PTS-f₁, and male PTS-f₂, we detail their genetically correlated and putatively causal profiles below.

Female $PTS-f_2$ was enriched for cardiovascular genetic correlates and reinforced well-studied relationships between cardiovascular health and PTSD (30). Though correlated, these effects were not detected by enrichment tests of putatively causal trait relationships. We attribute this lack of enrichment to the also well documented difficulties in untangling the relationship between PTSD and cardiovascular disease. Briefly, despite evidence of causal effects measured by Mendelian randomization (30),

bidirectional effects persisted with certain cardiovascular phenotypes. In one attempt to resolve these effects, the onset of PTSD relative to onset of cardiovascular disease appeared to play some role in the observed bidirectional relationship between these traits (31).

Male $PTS-f_1$ and $PTS-f_2$ were genetically correlated with psychiatric traits. Male $PTS-f_1$ was not enriched for any genetic correlates but did have specific enrichment of putative causal effects with medication use traits localized to pain relief medications: tramadol (a synthetic opioid), omegrazole (a proton pump inhibitor), and aspirin. Low-dose aspirin is often used for the prevention of myocardial infarction, as well as an over-the-counter analgesic commonly taken by PTSD patients (32–34). Patients with PTSD report higher use of opioid and non-opioid analgesics relative to non-PTSD patients (35). The relationship between opioid use and PTSD is complex and multidirectional, as opioids may be used to address pain caused by PTSD, while also potentially being related to the traumatic event(s) leading to PTSD. Our putative causal estimates between pain medication and PTS using the LCV approach were bidirectional and consistent with literature reports of chronic pain and internalizing disorders such as depression (36). These findings reinforce several scenarios of their possible causal relationship including: (i) an index trauma causes chronic pain and leads to elevated PTS, (ii) chronic pain (e.g., lower back pain, migraines) itself is a traumatic experience contributing to PTS, and (iii) intrusive and hyperarousal symptoms cause pain complaints and/or pain catastrophizing, respectively (37). These relationships are largely considered evidence of shared vulnerability and are reviewed in greater detail by Asmundson et al. (38). Male PTS-f₂ was enriched for musculoskeletal traits at the level of genetic correlation and putative causality. Unlike male PTS-f₁, these results highlight effects of stress on dental health and mid-to-low back pain (39,40). In sum, male PTS findings support the role of pain in PTS. There appears to be pain areaspecific and factor-specific effects, but these require further investigation to verify.

LCV analyses uncovered several sex-based differences in PTSD biology, etiology, and symptomatology. While it was expected for psychiatric enrichment to be present in both sexes, the observations within this trait domain differ. In males, for example, the most significant concordant traits were tiredness/lethargy, trouble relaxing, and low energy, potentially corresponding to depression, anxiety, and sleep-related symptoms. In females, the most significant concordant traits were suffering from nerves, familial abuse as a child, and decreased ability to confide. These findings in females correspond not only to anxiety-related traits, but also treatment, coping mechanisms, and trauma exposure. The genetic causal effects related to familial abuse provide support for studies showing that greater genetic liability for PTSD in women may contribute to earlier onset and/or more severe symptoms,

as well as women more generally experiencing trauma early in life (41). Further, we found that many of the significantly associated traits in women were anxiety-related (e.g. suffering from nerves, extended periods of anxiety, tenseness/restlessness were associated with both PTS-f₁ and PTS-f₂), supporting findings that women are more prone to anxious symptoms of PTSD (42,43). These findings may also simply reflect the increased prevalence of anxiety disorders in women, as well as the strong comorbidity between PTSD and anxiety disorders (44,45). Further study of female- and male-specific disorder and symptom factor structures may aid in untangling these observations.

Our study has three primary limitations to consider. First, the UKB dataset primarily represents European ancestry individuals of a generally higher socioeconomic bracket (46). This means that PTS symptoms are more likely (i) relatively mild due to lower prevalence of exposure to traumatic events and (ii) reflective of civilian trauma patterns; military cohorts have been observed to experience greater resilience to trauma, thereby altering PTSD etiology (47). Our results may therefore only largely apply to a European population and/or to higher socioeconomic status groups. Second, the UKB has information for a diverse collection of adult and childhood events that could be considered traumatic, but there is no information on the quantity or severity of the events. This information may demonstrate that the PTS symptoms reported by UKB participants are enriched for certain types of experiences. PTS patterns following specific traumas or trauma domains therefore warrant dedicated investigation; however, biobank-type datasets are required to achieve adequate power for these kinds of studies, and this level of phenotype detail is rare in biobank contexts. Finally, on a statistical level, indicator GWAS used to estimate PTS factor structure fit a linear model to ordinally distributed data. With sample sizes as large as the UKB, this mismatch of model suitability may not be able to control type I error rate for rarer variants (48). Therefore, the genetic signal of the PTS indicators used here may not fully reflect their true polygenic nature.

In summary, we demonstrate different PTS genetic factor structures between sexes, highlighting the importance of explicitly considering sex in genetic studies of PTSD. By modeling genetic correlation and putative causal relationships of each factor in males and females, we present preliminary data to inform how different dimensions of PTS may influence other traits, behaviors, and disorders. These data inform the etiological differences between males and females supported by existing literature and introduce new hypotheses to help understand the biology of PTS and PTSD.

ACKNOWLEDGEMENTS

This project is partially supported by funding from the University of Toronto Data Sciences Institute.

DISCLOSURES

Dr. Stein has in the past 3 years received consulting income from Acadia Pharmaceuticals, Aptinyx, atai Life Sciences, BigHealth, Biogen, Bionomics, BioXcel Therapeutics, Boehringer Ingelheim, Clexio, Eisai, EmpowerPharm, Engrail Therapeutics, Janssen, Jazz Pharmaceuticals, NeuroTrauma Sciences, PureTech Health, Sage Therapeutics, Sumitomo Pharma, and Roche/Genentech. Dr. Stein has stock options in Oxeia Biopharmaceuticals and EpiVario. He has been paid for his editorial work on *Depression and Anxiety* (Editor-in-Chief), *Biological Psychiatry* (Deputy Editor), and *UpToDate* (Co-Editor-in-Chief for Psychiatry).

Dr. Gelernter is paid for editorial work (Complex Psychiatry).

The other authors have no competing interests to report.

AUTHOR CONTRIBUTIONS

FRW and AM designed the project. FRW and AM collected the data and performed all analyses. AM, MBS, JG, and FRW interpreted the analyses. AM and FRW wrote the paper. AM, MBS, JG, and FRW edited the paper. FRW supervised the study.

DATA AVAILABILITY

PTS factor summary statistics can be accessed via Zenodo: 10.5281/zenodo.8061505.

REFERENCES

1. Koenen KC, Ratanatharathorn A, Ng L, McLaughlin KA, Bromet EJ, Stein DJ, et al. Posttraumatic stress disorder in the World Mental Health Surveys. Psychol Med. 2017 Oct;47(13):2260–74.

2. Mauritz MW, Goossens PJJ, Draijer N, Van Achterberg T. Prevalence of interpersonal trauma exposure and trauma-related disorders in severe mental illness. Eur J Psychotraumatology. 2013 Dec 1;4(1):19985.

3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders [Internet]. Fifth Edition. American Psychiatric Association; 2013 [cited 2023 Jul 20]. Available from: https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890425596

4. Stein MB, Jang KL, Taylor S, Vernon PA, Livesley WJ. Genetic and Environmental Influences on Trauma Exposure and Posttraumatic Stress Disorder Symptoms: A Twin Study. Am J Psychiatry. 2002 Oct;159(10):1675–81.

5. Roberts AL, Rosario M, Corliss HL, Koenen KC, Austin SB. Elevated Risk of Posttraumatic Stress in Sexual Minority Youths: Mediation by Childhood Abuse and Gender Nonconformity. Am J Public Health. 2012 Aug;102(8):1587–93.

6. Dunn EC, Nishimi K, Powers A, Bradley B. Is developmental timing of trauma exposure associated with depressive and post-traumatic stress disorder symptoms in adulthood? J Psychiatr Res. 2017 Jan;84:119–27.

7. King MW, Street AE, Gradus JL, Vogt DS, Resick PA. Gender Differences in Posttraumatic Stress Symptoms Among OEF/OIF Veterans: An Item Response Theory Analysis: Gender Differences in Veterans' PTSD Symptoms. J Trauma Stress. 2013 Apr;26(2):175–83.

8. Duncan LE, Ratanatharathorn A, Aiello AE, Almli LM, Amstadter AB, Ashley-Koch AE, et al. Largest GWAS of PTSD (N=20 070) yields genetic overlap with schizophrenia and sex differences in heritability. Mol Psychiatry. 2018 Mar;23(3):666–73.

9. Nievergelt CM, Maihofer AX, Klengel T, Atkinson EG, Chen CY, Choi KW, et al. International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci. Nat Commun. 2019 Oct 8;10(1):4558.

10. Levey DF, Stein MB, Wendt FR, Pathak GA, Zhou H, Aslan M, et al. Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. Nat Neurosci. 2021 Jul;24(7):954–63.

11. Stein MB, Levey DF, Cheng Z, Wendt FR, Harrington K, Pathak GA, et al. Genome-wide association analyses of post-traumatic stress disorder and its symptom subdomains in the Million Veteran Program. Nat Genet. 2021 Feb;53(2):174–84.

12. Wendt FR, Garcia-Argibay M, Cabrera-Mendoza B, Valdimarsdóttir UA, Gelernter J, Stein MB, et al. The Relationship of Attention-Deficit/Hyperactivity Disorder With Posttraumatic Stress Disorder: A Two-Sample Mendelian Randomization and Population-Based Sibling Comparison Study. Biol Psychiatry. 2023 Feb 15;93(4):362–9.

13. Nievergelt CM, Maihofer AX, Mustapic M, Yurgil KA, Schork NJ, Miller MW, et al. Genomic predictors of combat stress vulnerability and resilience in U.S. Marines: A genome-wide association study across multiple ancestries implicates PRTFDC1 as a potential PTSD gene. Psychoneuroendocrinology. 2015 Jan 1;51:459–71.

14. Christiansen DM, Hansen M. Accounting for sex differences in PTSD: A multi-variable mediation model. Eur J Psychotraumatology. 2015 Dec 1;6(1):26068.

15. Polimanti R, Wendt FR. Posttraumatic stress disorder: from gene discovery to disease biology. Psychol Med. 2021 Oct;51(13):2178–88.

16. Overstreet C, Levey DF, Zhou H, Harrington KM, Quaden R, Stein MB, et al. Factor structure of the posttraumatic stress disorder checklist (PCL-17) in 279,897 million veteran program participants. Psychiatry Res. 2023 Jan 1;319:114994.

17. Grotzinger AD, Rhemtulla M, de Vlaming R, Ritchie SJ, Mallard TT, Hill WD, et al. Genomic structural equation modelling provides insights into the multivariate genetic architecture of complex traits. Nat Hum Behav. 2019 May;3(5):513–25.

18. Davis KAS, Coleman JRI, Adams M, Allen N, Breen G, Cullen B, et al. Mental health in UK Biobank – development, implementation and results from an online questionnaire completed by 157 366 participants: a reanalysis. BJPsych Open. 2020 Feb 6;6(2):e18.

19. Schwaba T, Mallard TT, Maihofer AX, Rhemtulla M, Lee PH, Smoller JW, et al. Comparison of the Multivariate Genetic Architecture of Eight Major Psychiatric Disorders Across Sex [Internet]. Genetic and Genomic Medicine; 2023 Jun [cited 2023 Jul 20]. Available from: http://medrxiv.org/lookup/doi/10.1101/2023.05.25.23290545

20. O'Connor LJ, Price AL. Distinguishing genetic correlation from causation across 52 diseases and complex traits. Nat Genet. 2018 Dec;50(12):1728–34.

21. Wendt FR, De Lillo A, Pathak GA, De Angelis F, COVID-19 Host Genetics Initiative, Polimanti R. Host Genetic Liability for Severe COVID-19 Associates with Alcohol Drinking Behavior and Diabetic Outcomes in Participants of European Descent. Front Genet [Internet]. 2021 [cited 2023 Jul 20];12. Available from: https://www.frontiersin.org/articles/10.3389/fgene.2021.765247

22. Wendt FR, Pathak GA, Lencz T, Krystal JH, Gelernter J, Polimanti R. Multivariate genome-wide analysis of education, socioeconomic status and brain phenome. Nat Hum Behav. 2021 Apr;5(4):482–96.

23. Xu F, Zhang L, Xu Y, Song D, He W, Ji X, et al. Hypermethylation of SCAND3 and Myo1g Gene Are Potential Diagnostic Biomarkers for Hepatocellular Carcinoma. Cancers. 2020 Aug;12(8):2332.

24. Kangas M, Henry JL, Bryant RA. Posttraumatic stress disorder following cancer: A conceptual and empirical review. Clin Psychol Rev. 2002 May 1;22(4):499–524.

25. Kaster TS, Sommer JL, Mota N, Sareen J, El-Gabalawy R. Post-traumatic stress and cancer: Findings from a cross-sectional nationally representative sample. J Anxiety Disord. 2019 Jun 1;65:11–8.

26. Brown LC, Murphy AR, Lalonde CS, Subhedar PD, Miller AH, Stevens JS. Posttraumatic Stress Disorder and Breast Cancer: Risk Factors and the Role of Inflammation and Endocrine Function. Cancer. 2020 Jul 15;126(14):3181–91.

27. Yang Z, Wu H, Lee PH, Tsetsos F, Davis LK, Yu D, et al. Investigating Shared Genetic Basis Across Tourette Syndrome and Comorbid Neurodevelopmental Disorders Along the Impulsivity-Compulsivity Spectrum. Biol Psychiatry. 2021 Sep 1;90(5):317–27. 28. Carleial S, Nätt D, Unternährer E, Elbert T, Robjant K, Wilker S, et al. DNA methylation changes following narrative exposure therapy in a randomized controlled trial with female former child soldiers. Sci Rep. 2021 Sep 16;11(1):18493.

29. Urbanek ME, Zuo J. Genetic predisposition to tinnitus in the UK Biobank population. Sci Rep. 2021 Sep 13;11(1):18150.

30. Seligowski AV, Misganaw B, Duffy LA, Ressler KJ, Guffanti G. Leveraging Large-Scale Genetics of PTSD and Cardiovascular Disease to Demonstrate Robust Shared Risk and Improve Risk Prediction Accuracy. Am J Psychiatry. 2022 Nov 1;179(11):814–23.

31. Polimanti R, Wendt FR, Pathak GA, Tylee DS, Tcheandjieu C, Hilliard AT, et al. Understanding the comorbidity between posttraumatic stress severity and coronary artery disease using genome-wide information and electronic health records. Mol Psychiatry. 2022 Oct;27(10):3961–9.

32. Shemesh E, Koren-Michowitz M, Yehuda R, Milo-Cotter O, Murdock E, Vered Z, et al. Symptoms of Posttraumatic Stress Disorder in Patients Who Have Had a Myocardial Infarction. Psychosomatics. 2006 May 1;47(3):231–9.

33. Shemesh E, Yehuda R, Milo O, Dinur I, Rudnick A, Vered Z, et al. Posttraumatic Stress, Nonadherence, and Adverse Outcome in Survivors of a Myocardial Infarction. Psychosom Med. 2004 Aug;66(4):521.

34. Cotter G, Milo-Cotter O, Rubinstein D, Shemesh E. Posttraumatic Stress Disorder: A Missed Link Between Psychiatric and Cardiovascular Morbidity? CNS Spectr. 2006 Feb;11(2):129–36.

35. Schwartz AC, Bradley R, Penza KM, Sexton M, Jay D, Haggard PJ, et al. Pain Medication Use Among Patients With Posttraumatic Stress Disorder. Psychosomatics. 2006 Apr;47(2):136.

36. Zhao SS, Holmes MV, Alam U. Disentangling the relationship between depression and chronic widespread pain: A Mendelian randomisation study. Semin Arthritis Rheum. 2023 Jun;60:152188.

37. Jenewein J, Erni J, Moergeli H, Grillon C, Schumacher S, Mueller-Pfeiffer C, et al. Altered Pain Perception and Fear-Learning Deficits in Subjects With Posttraumatic Stress Disorder. J Pain. 2016 Dec 1;17(12):1325–33.

38. PTSD and the Experience of Pain: Research and Clinical Implications of Shared Vulnerability and Mutual Maintenance Models [Internet]. [cited 2023 Jul 20]. Available from: https://journals.sagepub.com/doi/epdf/10.1177/070674370204701004

39. de Oliveira Solis AC, Araújo ÁC, Corchs F, Bernik M, Duran ÉP, Silva C, et al. Impact of posttraumatic stress disorder on oral health. J Affect Disord. 2017 Sep;219:126–32.

40. Tagger-Green N, Nemcovsky C, Fridenberg N, Green O, Chaushu L, Kolerman R. Oral and Dental Considerations of Combat-Induced Post Traumatic Stress Disorder (PTSD)—A Cross-Sectional Study. J Clin Med [Internet]. 2022 Jun [cited 2023 Jul 20];11(11). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181801/

41. Koenen KC, De Vivo I, Rich-Edwards J, Smoller JW, Wright RJ, Purcell SM. Protocol for investigating genetic determinants of posttraumatic stress disorder in women from the Nurses' Health Study II. BMC Psychiatry. 2009 May 29;9(1):29.

42. Olff M. Sex and gender differences in post-traumatic stress disorder: an update. Eur J Psychotraumatology. 2017 Sep 29;8(sup4):1351204.

43. El-Khoury F, Rieckmann A, Bengtsson J, Melchior M, Rod NH. Childhood adversity trajectories and PTSD in young adulthood: A nationwide Danish register-based cohort study of more than one million individuals. J Psychiatr Res. 2021 Apr 1;136:274–80.

44. McLean CP, Asnaani A, Litz BT, Hofmann SG. Gender Differences in Anxiety Disorders: Prevalence, Course of Illness, Comorbidity and Burden of Illness. J Psychiatr Res. 2011 Aug;45(8):1027– 35.

45. McMillan KA, Sareen J, Asmundson GJG. Social Anxiety Disorder Is Associated With PTSD Symptom Presentation: An Exploratory Study Within A Nationally Representative Sample. J Trauma Stress. 2014;27(5):602–9.

46.: Data-Field 21000 [Internet]. [cited 2023 Jul 20]. Available from: https://biobank.ndph.ox.ac.uk/crystal/field.cgi?id=21000

47. Green KT, Calhoun PS, Dennis MF, Research the MAMI, Education, Workgroup CC, et al. Exploration of the Resilience Construct in Posttraumatic Stress Disorder Severity and Functional Correlates in Military Combat Veterans Who Have Served Since September 11, 2001. J Clin Psychiatry. 2010 Jun 15;71(7):6966.


48. Bi W, Zhou W, Dey R, Mukherjee B, Sampson JN, Lee S. Efficient mixed model approach for large-scale genome-wide association studies of ordinal categorical phenotypes. Am J Hum Genet. 2021 May 6;108(5):825–39.


FIGURES

Figure 1. Two-factor model of posttraumatic stress in females (yellow) and males (purple). Standardized loadings are shown for each indicator: CON = trouble concentrating, DIS = feeling distant from others, IRR = irritability, THO = recent distributing thoughts, UPS = recent upset feelings, AVO = avoidance. Significant factor loadings (p<0.05) are shown in solid black lines while dashed grey lines show loadings suggested by EFA but did not reach statistical significance (p>0.05) in CFA.

Figure 2. Patterns of trait domain enrichment among genetic correlates of male (purple) and female (yellow) posttraumatic stress (PTS) factors. Fold enrichments were calculated using hypergeometric tests (Table S12) with asterisks indicating significant enrichment (P<0.05).

Figure 3. Patterns of significant trait domain genetic causality proportions (gĉps) from latent causal variable analysis of female (left) and male (right). Top-right: caused by f_1 , caused by f_2 . Top-left: causes f_1 , caused by f_2 . Bottom-right: caused by f_1 , causes f_2 . Bottom-left: causes f_1 , causes f_2 . Select traits are highlighted in each quadrant. All gĉp results are shown in Tables S13 and S14.





PTS f1 & f2 PTS f1 only PTS f2 only

■ PTS f1 & f2 ■ PTS f1 only

PTS f2 only

